CD34⁺ cells contribute to cardiac remodeling during disease development

Area of Science:

• Cardiovascular Biology
• Stem Cell Biology
• Immunology

Background:

• CD34 is a marker for hematopoietic stem cells but also identifies diverse tissue-resident progenitors.
• Current CD34-targeted therapies lack specificity, failing to distinguish reparative from pathogenic cell subsets.
• Cardiac remodeling involves multiple CD34+ cell lineages, including endothelial, hematopoietic, and fibroblast progenitors.

Purpose of the Study:

• To review the multifaceted roles of CD34+ cell lineages in cardiac homeostasis and pathological remodeling.
• To integrate evidence on CD34+ cell contributions to vascular integrity, immune response, and fibrosis.
• To propose a shift towards lineage-specific therapeutic strategies for cardiac repair.

Main Methods:

• Literature review integrating histological, mechanistic, and clinical evidence.
• Analysis of recent advances in lineage tracing and single-cell genomics.
• Discussion of surface marker refinement for progenitor cell isolation.

Main Results:

• Non-bone marrow-derived endothelial progenitor cells (EPCs) support vascular integrity and neovascularization.
• Hematopoietic progenitors generate inflammatory cells crucial for immune responses post-injury.
• Resident fibroblast progenitor cells (FPCs) contribute to cardiac fibrosis.

Conclusions:

• CD34+ cells play diverse roles in cardiac remodeling, encompassing both repair and fibrosis.
• Refining marker panels is essential to isolate beneficial endothelial progenitors and exclude detrimental subsets.
• Future cardiac therapies should focus on lineage-specific CD34+ cell targeting rather than generic enrichment.